Anzeige
Mehr »
Donnerstag, 07.08.2025 - Börsentäglich über 12.000 News
Große CEO-Enthüllung: Analysten sehen +56% Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D4G4 | ISIN: US13471N3008 | Ticker-Symbol: CF5
NASDAQ
06.08.25 | 21:36
0,688 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CAN-FITE BIOPHARMA LTD ADR Chart 1 Jahr
5-Tage-Chart
CAN-FITE BIOPHARMA LTD ADR 5-Tage-Chart

Aktuelle News zur CAN-FITE BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
CAN-FITE BIOPHARMA Aktie jetzt für 0€ handeln
30.07.Can-Fite reaches 50% enrollment milestone in pancreatic cancer trial4
30.07.Can-Fite BioPharma Ltd.: Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone229Primary endpoint is safety; Namodenoson continues to demonstrate a favorable safety profile Ramat Gan, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:...
► Artikel lesen
28.07.Can-Fite Prices $5 Mln Offering Of ADSs And Warrants With Potential $10 Mln Upside1
28.07.Can-Fite BioPharma prices $5 million public offering of ADSs1
28.07.Can-Fite BioPharma Ltd.: Can-Fite Announces Up To $15.0 Million Public Offering1
28.07.Can-Fite BioPharma Ltd.: Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia573Ramat Gan, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule...
► Artikel lesen
28.07.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer1
25.07.Can-Fite BioPharma Ltd. - F-1/A, Registration statement for certain foreign private issuers1
23.07.Can-Fite BioPharma launches best-efforts offering of ADSs and warrants1
23.07.Can-Fite BioPharma Ltd. - F-1, Registration statement for certain foreign private issuers1
30.06.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer1
23.06.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer3
16.06.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer1
16.05.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer1
05.05.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer1
17.04.Can-Fite BioPharma Ltd.: Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients112Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs...
► Artikel lesen
14.04.Can-Fite BioPharma Ltd.: Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares2
14.04.Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.67M1
14.04.Can-Fite BioPharma Ltd.: Can-Fite Reports 2024 Financial Results and Clinical Update261RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs...
► Artikel lesen
14.04.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer2
Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1